Drug Designing: Open Access

Computationally Designed Enzyme Models to Replace Natural Enzymes in Prodrug Approaches

Rafik Karaman*

Bioorganic Chemistry Department, Faculty of Pharmacy, Al-Quds University, P.O. Box 20002, Jerusalem, Palestine

Introduction

The striking efficiency of enzyme catalysis has inspired many organic chemists to explore enzyme mechanisms by studying certain intra molecular processes such as enzyme models which proceed faster than their intermolecular counterparts. This research brings about the important question of whether enzyme models will replace natural enzymes in the conversion of prodrugs to their parental drugs.

Enzymes are mandatory for the inter conversion of many prodrugs to their parental drugs. Among the most important enzymes in the bioconversion of prodrugs are amides (ex. trypsin, chymotrypsin, elastase, carboxypeptidase, and aminopeptidase) and ester-based prodrugs (ex. paraoxonase, carboxylesterase, acetylcholinesterase and cholinesterase). Most of these enzymes are hydrolytic enzymes, however, non-hydrolytic enzymes, including all cytochrome P450 enzymes, are also capable of catalyzing the bioconversion of ester and amide-based prodrugs [1].

Today, the consensus is that the catalytic activity of an enzyme is based on the combined effects of catalysis by functional groups and the ability to reroute intermolecular reactions through alternative pathways by which substrates bind to preorganized active sites. Rate acceleration by enzymes can be due to (a) covalently enforced proximity, as in chymotrypsin, [2] (b) non-covalently enforced proximity, as in the catalytic activity of metallo-enzymes, [3] (c) covalently enforced strain, and [4] (d) non-covalently enforced strain, which has been heavily studied in models that mimic the enzyme lysozyme [5].

The rate constants for a large majority of enzymatic reactions exceed 10^{10} to 10^{18} fold the non-enzymatic bimolecular counterparts. For example, reactions catalyzed by cyclophilin are enhanced by 10^5 and those by orotidine monophosphatedecarboxylase are enhanced by 10^{17} [6]. The significant rate of acceleration achieved by enzymes is brought about by the binding of the substrate within the confines of the enzyme pocket called the active site. The binding energy of the resulting enzyme-substrate complex is the dominant driving force and the major contributor to catalysis. It is believed that in all enzymatic reactions, binding energy is used to overcome prominent physical and thermodynamic factors that create barriers for the reaction [7] (ΔG). The striking efficiency of enzyme catalysis has inspired many organic chemists to explore enzyme mechanism(s) by studying certain intra molecular processes (enzyme models) which proceed faster than their intermolecular counterparts. Both, enzymes and intra molecular processes are similar in that the reacting centers are held together (covalently with intra molecular systems, and non-covalently with enzymes) [8].

During the last six decades, reaction models for mimicking enzyme catalysis has been advocated by a variety of chemists. Among enzyme models based on enthalpic driving forces are: (1) near attack proximity orientation model proposed by Bruice's group [9,10]; (2) orbital steering theory proposed by Koshland's group [11]; (3) spatiotemporal hypothesis devised by Menger et al. [12,13-18]; and (4) stereo population control suggested by Cohen's group [19-21]. Mechanistic studies

based on these models have played an important role in elucidating the chemistry of the groups involved in enzyme catalysis as well as in unraveling the mechanisms available for particular processes. Based on these studies, it seems reasonable to assume that an understanding of efficiency depends on the structure in intramolecular catalysis, which draws the basis for utilizing these enzyme models as linkers to certain drugs for synthesizing prodrugs with higher bioavailability than their corresponding parental drugs. In addition, it was found that slight changes in the structural features of the enzyme model could provide a broad range of reaction rates ranging from 1 to 10^{15} [22]. With such a broad range, prodrugs will be designed so that they will undergo non-enzymatic (chemical) conversion to their parental drugs in a fast or slow manner according to the required goal.

Prodrugs are bio reversible derivatives of drug molecules designed to overcome pharmaceutical, pharmacokinetic or pharmacodynamic barriers, such as low oral absorption, lack of site specificity, insufficient chemical stability, poor solubility, toxicity, and unacceptable taste/odor. The prodrug approach is becoming more popular and successful, as prodrugs comprise around 10% of the world's marketed medications and 20% of all small molecular medications approved between 2000 and 2008 [23,24].

An ideal drug candidate needs to have specific properties, including chemical and enzymatic stability, solubility, low clearance by the liver or kidney, permeation across biological membranes, potency, and safety.

The conversion of a prodrug to the parental drug at the target site is crucial for the prodrug approach to be successful. Generally, activation involves metabolism by enzymes that are distributed throughout the body. Many prodrugs contain ester or amide bonds, which are formed by derivatizing a hydroxyl, carboxyl, or amine group present in the parental drug. When the ester or amide bond of the prodrug is cleaved, the active parental drug is released. In vivo cleavage of ester and amide bonds generally occurs through hydrolysis or oxidation. Many ester and amide-based prodrugs have been developed after being designed to improve the oral bioavailability of drugs [25-27]. The major problem with these prodrugs is the difficulty in predicting their bioconversion rates, and thus their pharmacological or toxicological effects. Moreover, the rate of hydrolysis is not always predictable, and bioconversion can

*Corresponding author: Rafik Karaman, Bioorganic Chemistry Department, Faculty of Pharmacy, Al-Quds University, P.O. Box 20002, Jerusalem, Palestine, Fax: 972-2790413, E-mail: dr_karaman@yahoo.com

be affected by various factors such as age, health conditions and gender [28–30].

Modern computational methods can be used for the design of innovative prodrugs for drugs that contain hydroxyl, phenol, or amine groups. For example, mechanisms of some enzyme models that have been used to gain a better understanding of enzyme catalysis have been recently investigated and utilized for the design of novel prodrug linkers [31-37]. Using computational methods such as DFT, molecular mechanics and ab initio, various enzyme models were investigated for assigning the factors affecting the rate-determining step and playing dominant roles in governing the reaction rate. Among these enzyme models are: (a) proton transfer between two oxygens in Kirby's acetals [38-47] and proton transfer between nitrogen and oxygen in [38-47]; (b) intramolecular acid-catalyzed hydrolysis in some of Kirby's maleamic acid amide derivatives [38-47]; (c) proton transfer between two oxygens in rigid systems as investigated by Menger [12-18]; (d) the acid-catalyzed lactonization of hydroxy-acids as studied by Cohen et al. [19] and Menger [12]; and (e) the SN2-based cyclization as studied by Brown [48], Bruice and Mandolini [9,49].

These studies have revealed the following conclusions: (i) rate enhancement in intramolecular processes is a result of both entropy and enthalpy effects. In intramolecular cyclization processes where enthalpic effects were predominant, steric effects were the determining factor for the acceleration, whereas proximity orientation was the determining factor in proton-transfer reactions. (ii) The distance between the two reacting centers is the main factor in determining whether the reaction type is intermolecular or intramolecular. When the distance exceeded 3 Å, an intermolecular engagement was preferred because of the involvement of a water molecule (solvent). When the distance between the electrophile and nucleophile was <3 Å, an intramolecular engagement was preferred. (iii) The efficiency of proton transfer between two oxygens and between nitrogen and oxygen in Kirby's enzyme models is attributed to a relatively strong hydrogen bonding in the products and the transition states leading to them [31-37].

It was concluded from the studies on intramolecularity that there is a need to further investigate the reaction mechanism for assigning the factors determining the reaction rate. This would allow for better design of an efficient chemical device that can be used as a prodrug linker and that will have the potential to chemically and not enzymatically liberate the active drug in a programmable and controlled manner. For example, the mechanism for proton transfer in Kirby's acetals were explored and directed the synthesis of novel prodrugs of aza-nucleosides for the treatment of myelodysplastic syndromes where the prodrug linker is attached to the hydroxyl group of the nucleoside [50]. The prodrugs were designed such that they undergo cleavage reactions in physiological environments such as stomach, intestine, and/or blood circulation, with rates that are solely dependent on the structural features of the pharmacologically inactive linker. Different linkers were also investigated for the design of a large number of prodrugs such as anti-Parkinson (dopamine), [51] anti-viral (acyclovir), and [52] anti-malarial (atovaquone) with enhanced dissolution, membrane penetration, and bioavailability [53]. In addition, prodrugs for masking the bitter taste of atenolol, dopamine, pseudoephedrine, amoxicillin, cephalexin, cefaclor, and paracetamol were also designed and synthesized [54,55]. The role of the linkers in these prodrugs is to block the free amine or phenol group, which is responsible for the bitter taste of the drug, in the corresponding parental drugs and to enable the release of the drug in a programmable manner [50-55].

These examples highlight the great potential and impact of modern computational approaches for prodrug design. Furthermore, with the possibility of designing prodrugs that have different linkers, the rate of release of the parental drugs can be controlled without the presence of an enzyme.

Acknowledgement

References

1. Liederer BM, Borchardt RT (2006) Enzymes Involved in the Bioconversion of Ester-Based Prodrugs. J Pharma Sci 95: 1177-1195.

2. Blow DM, Birktoff JJ, Hartly BS (1969) Role of a Buried Acid Group in the Mechanism of Action of Chymotrypsin. Nature 221: 337-340.

3. Page MI (1984) The Chemistry of Enzyme Action. Elsevier 6: 2-5.

4. Gandour RD, Schowen RL (1978) Transition States of Biochemical Processes, Plenum Press, New York.

5. Kirby AJ (1996) Enzyme Mechanisms, Models, and Mimics. Angewandte Chemie International Edition in English 35: 706-724.

6. Nelson DL, Cox MM (2003) Lehninger Principles of Biochemistry, Worth Publishers, New York.

7. Fersht A (1999) Structure and Mechanism in Protein Science: A guide to Enzyme Catalysis and Protein Folding. W.H. Freeman and Company, New York.

8. Czarnik AW, Liebman JF, Greenberg A (1989) Mechanistic Principles of Enzyme Activity. VCH Publishers, New York.

9. Bruice TC, Pandit UK (1960) The effect of geminal substitution ring size and rotamer distribution on the intra molecular nucleophilic catalysis of the hydrolysis of monophenyl esters of dibasic acids and the solvolysis of the intermediate anhydrides. J Am Chem Soc 82: 5858–5865.

10. Bruice TC, Pandit UK (1960) Intramolecular models depicting the kinetic importance of "Fit" in enzymatic catalysis. Proc Natl Acad Sci USA 46: 402–404.

11. Dafforn A, Koshland Jr DE (1973) Proximity, entropy and orbital steering. Biochem Biophys Res Commun 52: 779-785.

12. Menger FM, Ladika M (1988) Fast hydrolysis of an aliphatic amide at neutral pH and ambient temperature. A peptidase model. J Am Chem Soc 110: 6794-6796.

13. Menger FM (1985) On the source of intramolecular and enzymatic reactivity. Acc Chem Res 18: 128-134.

14. Menger FM, Chow JF, Kaiserman H, Vasquez PC (1983) Directionality of proton transfer in solution. Three systems of known angularity. J Am Chem Soc 105: 4996-5002.

15. Menger FM (1983) Directionality of organic reactions in solution. Tetrahedron 39: 1013-1040.

16. Menger FM, Grosssman J, Liotta DC (1983) Transition-state pliability in nitrogen-to-nitrogen proton transfer. J Org Chem 48: 905-907.

17. Menger FM, Galloway AL, Musaev DG (2003) Relationship between rate and distance. Chem Commun 2370-2371.

18. Menger FM (2005) An alternative view of enzyme catalysis. Pure Appl Chem 77: 1873-1876.

19. Milstein S, Cohen LA (1970) Concurrent general-acid and general-base catalysis of esterification. J Am Chem Soc 92: 4377-4382.

20. Milstein S, Cohen LA (1970) Rate acceleration by stereopopulation control: models for enzyme action. Proc Natl Acad Sci USA 67: 1143-1147.

21. Milstein S, Cohen LA (1972) Stereopopulation control I. Rate enhancement in the lactonizations of o-hydroxyhydrocinnamic acids. J Am Chem Soc 94: 9158-9165.

22. Kirby AJ, Hollfelder F (2009) From Enzyme Models to Model Enzymes. R Soc Chem 1-273.

23. Huttunen KM, Raunio H, Rautio J (2011) Prodrugs -- from serendipity to rational design. Pharmacol Rev 63: 750-71.

24. Stella VJ (2010) Prodrugs: some thoughts and current issues. J Pharm Sci 99: 4755-4765.

25. Beaumont K, Webster R, Gardner I, Dack K (2003) Design of ester prodrugs

to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 4: 461-485.

26. Gangwar S, Pauletti GM, Wang B, Siahaan TJ, Stella VJ, et al. (1997) Prodrug strategies to enhance the intestinal absorption of peptides. DDT 2: 148-155.

27. Wang W, Jiang J, Ballard CE, Wang B (1999) Prodrug approaches to the improved delivery of peptide drugs. Curr Pharm Des 5: 265-287.

28. Draganov DI, La Du BN (2004) Pharmacogenetics of paraoxonases: A brief review. Naunyn Schmiedebergs Arch Pharmacol 369: 78-88.

29. Ngawhirunpat T, Kawakami N, Hatanaka T, Kawakami J, Adachi I (2003) Age dependency of esterase activity in rat and human keratinocytes. Biol Pharm Bull 26: 1311-1314.

30. Moser VC, Chanda SM, Mortensen SR, Padilla S (1998) Age- and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities. Toxicol Sci 46: 211-222.

31. Karaman R (2008) Analysis of Menger's spatiotemporal hypothesis. Tetrahedron Lett 49: 5998-6002.

32. Karaman R (2009) Cleavage of Menger's aliphatic amide: a model for peptidase enzyme solely explained by proximity orientation in intramolecular proton transfer. J Mol Struct (THEOCHEM) 910: 27-33.

33. Karaman R (2010) The efficiency of proton transfer in Kirby's enzyme model, a computational approach. Tetrahedron Lett 51: 2130-2135.

34. Karaman R, Pascal RA (2010) Computational analysis of intramolecularity in proton transfer reactions. Org & Bimol Chem 8: 5174-5178.

35. Karaman R (2010) A General Equation Correlating Intramolecular Rates with Attack" Parameters: Distance and Angle. Tetrahedron Lett 51: 5185-5190.

36. Karaman R (2011) Analyzing the efficiency of proton transfer to carbon in Kirby's enzyme model- a computational approach. Tetrahedron Lett 52: 699-704.

37. Karaman R (2011) Analyzing the efficiency in intramolecular amide hydrolysis of Kirby's N-alkylmaleamic acids - A computational approach. Comput Theor Chem 974: 133-142.

38. Kirby AJ, Parkinson A (1994) Most efficient intramolecular general acid catalysis of acetal hydrolysis by the carboxyl group. J Chem Soc, Chem Commun 707-708.

39. Brown CJ, Kirby AJ (1997) Efficiency of proton transfer catalysis. Intramolecular general acid catalysis of the hydrolysis of dialkyl acetals of benzaldehyde. J Chem Soc, Perkin Trans 2, 1081-1094.

40. Craze G-A, Kirby AJ (1974) The role of the carboxy-group in intramolecular catalysis of acetal hydrolysis. The hydrolysis of substituted 2-methoxymethoxybenzoic acids. J Chem Soc, Perkin Trans 2: 61-66.

41. Barber SE, Dean KES, Kirby AJ (1999) A mechanism for efficient proton-transfer catalysis. Intramolecular general acid catalysis of the hydrolysis of 1-arylethyl ethers of salicylic acid. Can J Chem 77: 792-801.

42. Kirby AJ, da Silva D, Lima MF, Roussev CD, Nome F (2006) Efficient intramolecular general acid catalysis of nucleophilic attack on a phosphodiester. J Am Chem Soc 128: 16944-16952.

43. Kirby AJ, Williams NH (1994) Efficient intramolecular general acid catalysis of enol ether hydrolysis. Hydrogen-bonding stabilization of the transition state for proton transfer to carbon. J Chem Soc, Perkin Trans 2, 643-648.

44. Kirby AJ, Williams NH (1991) Efficient intramolecular general acid catalysis of vinyl ether hydrolysis by the neighbouring carboxylic acid group. J Chem Soc, Chem Commun 1643-1644.

45. Hartwell E, Hodgson DRW, Kirby AJ (2000) Exploring the limits of efficiency of proton-transfer catalysis in models and enzymes. J Am Chem Soc 122: 9326-9327.

46. Kirby AJ (1997) Efficiency of proton transfer catalysis in models and enzymes. Acc Chem Res 30: 290-296.

47. Asaad N, Davies JE, Hodgson DRW, Kirby AJ, Ottavi L, et al. (2005) The search for efficient intramolecular proton transfer from carbon: the kinetically silent intramolecular general base-catalysed elimination reaction of o-phenyl 8-dimethylamino-1-naphthaldoximes. J Phys Org Chem 18: 101-109.

48. Brown RF, van Gulick NM (1956) The geminal alkyl effect on the rates of ring closure of bromobutylamines. J Org Chem 21: 1046-1049.

49. Galli C, Mandolini L (2000) The role of ring strain on the ease of ring closure of bifunctional chain molecules. Eur J Org Chem 2000: 3117-3125.

50. Karaman R (2010) Prodrugs of Aza Nucleosides Based on Proton Transfer Reactions. J Comput Aided Mol Des 24: 961-970.

51. Karaman R (2011) Computational aided design for dopamine prodrugs based on novel chemical approach. Chem Biol Drug Des 78: 853-863.

52. Karaman R, Dajani KK, Qtait A, Khamis M (2012) Prodrugs of acyclovir - a computational approach. Chem Biol Drug Des 79: 819-834.

53. Karaman R, Hallak H (2010) Computer-assisted design of pro-drugs for antimalarial atovaquone. Chem Biol Drug Des 76: 350-360.

54. Karaman R, Dajani KK, Hallak H (2012) Computer-assisted design for atenolol prodrugs for the use in aqueous formulations. J Mol Model 18: 1523-1540.

55. Hejaz H, Karaman R, Khamis M (2012) Computer-assisted design for paracetamol masking bitter taste prodrugs. J Mol Model 18: 103-114.